Research
‘Too good to be true’: Biotech company’s paper on Parkinson’s retracted for data manipulation
Retraction Watch · By Marta Zherukha ·
The Brief
- Cell Reports, a Cell Press journal, has retracted a Parkinson's disease paper.
- The retraction notice says a coauthor found that first author Madhuja Samaddar changed data points to reduce variation in the work.
- The paper came from a biotech company, which the source URL identifies as Denali Therapeutics.
Why it matters
A retraction for manipulated data means the paper's findings on Parkinson's disease should no longer be relied on, and it is a reminder that data integrity checks can catch fabricated results.
Who’s affected
- researchers in neurodegeneration and Parkinson's disease
- readers who rely on published biomedical research
- #parkinsons
- #retraction
- #research-integrity
- #data-manipulation
- #neurodegeneration
A Cell Press journal has retracted a paper on Parkinson’s disease following the discovery that the first author manipulated data in the work. The retraction notice in Cell Reports states one of the coauthors found the first author, Madhuja Samaddar, changed data points to reduce…